Champions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2026

HACKENSACK, NJ / ACCESS Newswire / September 4, 2026 / Champions Oncology, Inc. (CSBR), a global leader in clinically relevant oncology research models and translational solutions, will report its financial and operational results for the quarter ended July 31, 2026, on Thursday, September 10, 2026, after market close.

Accesswire • Sep 4, 2026

CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push

Champions Oncology reports fourth-quarter fiscal 2026 growth as revenue gains, margin improvement and operational initiatives support progress.

Zacks Investment Research • Jul 30, 2026

Champions Oncology Q4 Earnings Call Highlights

Champions Oncology NASDAQ: CSBR reported record revenue for fiscal 2026 and positive adjusted EBITDA in every quarter of the year, supported by growth in its core Translational Oncology Solutions, or TOS, services business and efforts to bring radiopharmaceutical work in-house.

MarketBeat • Jul 27, 2026

Champions Oncology, Inc. (CSBR) Q4 2026 Earnings Call Transcript

Champions Oncology, Inc. (CSBR) Q4 2026 Earnings Call Transcript

Seeking Alpha • Jul 27, 2026

Champions Oncology Reports Record Annual Revenue of $59 Million

Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA HACKENSACK, NJ / ACCESS Newswire / July 27, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology research models and translational solutions, today announced its financial results for the fiscal year and fourth quarter ended April 30, 2026. Fourth Quarter and Other Financial Highlights: Record annual revenue of $59.4 million Fourth quarter revenue of $13.8 million Fourth quarter oncology services margin of 51% Adjusted EBITDA of $158,000 for the quarter and $1.6 million for the fiscal year Adjusted EBITDA income all four quarters in FY 2026 Continued investment in radiopharmaceuticals, the data platform and commercial organization Robert Brainin, CEO of Champions, commented, "Fiscal 2026 marked a year of meaningful progress in executing our strategic priorities as we delivered record annual revenue while continuing to invest in the capabilities we believe will support our next phase of growth.

Accesswire • Jul 27, 2026

2 Microcaps With Gross Margin Catalysts

CSBR and CEPL have levers in place for Gross Margin improvement.

Zacks Investment Research • Jul 23, 2026

CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?

Champions Oncology and Cytek Biosciences have different growth drivers and valuations, but which life sciences stock offers better long-term upside? Let's dive in.

Zacks Investment Research • Jul 23, 2026

Zacks Initiates Coverage of Champions Oncology With Neutral Recommendation

Discover why Zacks rates Champions Oncology as "Neutral", being the first on Wall Street to initiate coverage on the stock. Explore CSBR's accelerating pharmacology services and expanding data initiatives amid execution risks and commercialization timing.

Zacks Investment Research • Jul 22, 2026

Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Monday, July 27, 2026

HACKENSACK, NJ / ACCESS Newswire / July 20, 2026 / Champions Oncology, Inc. (NASDAQ:CSBR), a global leader in clinically relevant oncology research models and translational solutions, will report its financial and operational results for the quarter and year ended April 30, 2026, on Monday, July 27, 2026, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M.

Accesswire • Jul 20, 2026

Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026

Eight studies demonstrate how clinically relevant models and integrated data can reduce translational risk and guide development decisions HACKENSACK, NJ / ACCESS Newswire / April 9, 2026 / Champions Oncology, Inc. (Nasdaq:CSBR), a global leader in clinically relevant oncology research models and translational solutions, today announced it will present new data across eight poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place April 17-22, 2026, in San Diego, California. The presentations will highlight research across key areas of oncology drug development, including KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, antibody-drug conjugates (ADCs), and CAR-T therapies.

Accesswire • Apr 9, 2026